Inogen Inc (NASDAQ:INGN) EVP Matt Scribner sold 2,500 shares of Inogen stock in a transaction dated Tuesday, January 16th. The stock was sold at an average price of $116.17, for a total value of $290,425.00. Following the completion of the sale, the executive vice president now owns 7,297 shares of the company’s stock, valued at $847,692.49. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.
Matt Scribner also recently made the following trade(s):
- On Thursday, December 14th, Matt Scribner sold 2,500 shares of Inogen stock. The stock was sold at an average price of $120.34, for a total value of $300,850.00.
- On Monday, November 13th, Matt Scribner sold 2,500 shares of Inogen stock. The stock was sold at an average price of $112.35, for a total value of $280,875.00.
Shares of Inogen Inc (INGN) traded down $0.96 during trading hours on Friday, reaching $114.99. The company’s stock had a trading volume of 99,500 shares, compared to its average volume of 174,217. The stock has a market capitalization of $2,450.00, a PE ratio of 80.41, a price-to-earnings-growth ratio of 3.93 and a beta of 1.13. Inogen Inc has a fifty-two week low of $62.69 and a fifty-two week high of $130.05.
Inogen (NASDAQ:INGN) last posted its quarterly earnings data on Tuesday, November 7th. The medical technology company reported $0.33 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.29 by $0.04. Inogen had a return on equity of 13.37% and a net margin of 11.36%. The firm had revenue of $69.00 million for the quarter, compared to analysts’ expectations of $63.55 million. During the same period in the previous year, the firm earned $0.25 EPS. The business’s quarterly revenue was up 26.8% on a year-over-year basis. equities analysts expect that Inogen Inc will post 1.19 earnings per share for the current year.
Hedge funds have recently bought and sold shares of the company. Simplex Trading LLC purchased a new position in shares of Inogen during the 4th quarter valued at about $153,000. Schroder Investment Management Group purchased a new position in shares of Inogen during the 2nd quarter valued at about $132,000. Ameritas Investment Partners Inc. lifted its position in shares of Inogen by 6.1% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 1,495 shares of the medical technology company’s stock valued at $143,000 after buying an additional 86 shares in the last quarter. Victory Capital Management Inc. lifted its position in shares of Inogen by 17.8% during the 2nd quarter. Victory Capital Management Inc. now owns 2,036 shares of the medical technology company’s stock valued at $194,000 after buying an additional 307 shares in the last quarter. Finally, Pinebridge Investments L.P. lifted its position in shares of Inogen by 1.6% during the 2nd quarter. Pinebridge Investments L.P. now owns 2,143 shares of the medical technology company’s stock valued at $204,000 after buying an additional 33 shares in the last quarter.
Several research analysts have issued reports on the company. Zacks Investment Research cut Inogen from a “buy” rating to a “hold” rating in a research report on Wednesday, January 10th. BidaskClub cut Inogen from a “hold” rating to a “sell” rating in a research report on Saturday, January 6th. Leerink Swann reissued an “outperform” rating and issued a $120.00 target price (up from $115.00) on shares of Inogen in a research report on Wednesday, November 8th. Finally, Needham & Company LLC raised their target price on Inogen from $108.00 to $125.00 and gave the stock a “strong-buy” rating in a research report on Wednesday, November 8th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the company. The company presently has a consensus rating of “Hold” and an average price target of $102.71.
COPYRIGHT VIOLATION NOTICE: “Inogen Inc (INGN) EVP Matt Scribner Sells 2,500 Shares” was originally published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this news story on another site, it was illegally copied and republished in violation of US & international copyright and trademark laws. The original version of this news story can be viewed at https://www.dispatchtribunal.com/2018/01/19/inogen-inc-ingn-evp-matt-scribner-sells-2500-shares-2.html.
Inogen Company Profile
Inogen, Inc is a medical technology company. The Company develops, manufactures and markets portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The Company’s Inogen One systems concentrate the air around the patient to offer a single source of supplemental oxygen anytime, anywhere with a portable device.
Receive News & Ratings for Inogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen and related companies with MarketBeat.com's FREE daily email newsletter.